{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T02:05:31Z","timestamp":1789178731404,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T00:00:00Z","timestamp":1687219200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T00:00:00Z","timestamp":1687219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Insmed B.V."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Real-world data on antibiotic management of nontuberculous mycobacterial lung disease (NTM-LD) is limited for many countries. This study aimed to evaluate real-world treatment practices of NTM-LD in the Netherlands using medication dispensing data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective longitudinal real-world study was conducted using IQVIA\u2019s Dutch pharmaceutical dispensing database. The data are collected monthly and include approximately 70% of all outpatient prescriptions in the Netherlands. Patients initiated on specific NTM-LD treatment regimens between October 2015 and September 2020 were included. The main areas of investigation were initial treatment regimens, persistence on treatment, treatment switching, treatment compliance in terms of medication possession rate (MPR) and restarts of treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The database included 465 unique patients initiated on triple- or dual-drug regimens for the treatment of NTM-LD. Treatment switches were common and occurred approximately 1.6 per quarter throughout the treatment period. The average MPR of patients initiated on triple-drug therapy was 90%. The median time on therapy for these patients was 119 days; after six months and one year, 47% and 20% of the patients, respectively, were still on antibiotic therapy. Of 187 patients initiated on triple-drug therapy, 33 (18%) patients restarted antibiotic therapy after the initial treatment had been stopped.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>When on therapy, patients were compliant with the NTM-LD treatment; however, many patients stopped their therapy prematurely, treatment switches often occurred, and part of patients had to restart their therapy after a longer treatment gap. NTM-LD management should be improved through greater guideline adherence and appropriate involvement of expert centers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12890-023-02460-1","type":"journal-article","created":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T12:02:43Z","timestamp":1687262563000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Real-world treatment patterns in patients with nontuberculous mycobacterial lung disease in the Netherlands based on medication dispensing data"],"prefix":"10.1186","volume":"23","author":[{"given":"W","family":"Hoefsloot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Dacheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"van der Laan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Krol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"van Ingen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Obradovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ximeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,20]]},"reference":[{"issue":"11","key":"2460_CR1","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1080\/17476348.2021.1987891","volume":"15","author":"J van Ingen","year":"2021","unstructured":"van Ingen J, Obradovic M, Hassan M, Lesher B, Hart E, Chatterjee A, et al. Nontuberculous mycobacterial lung disease caused by Mycobacterium avium complex - disease burden, unmet needs, and advances in treatment developments. Expert Rev Respir Med. 2021;15(11):1387\u2013401. https:\/\/doi.org\/10.1080\/17476348.2021.1987891.","journal-title":"Expert Rev Respir Med"},{"key":"2460_CR2","unstructured":"Johnson MM, Odell JA. (2014) Nontuberculous mycobacterial pulmonary infections. Journal of Thoracic Disease; Vol\u00a06, No 3 (March 2014): J of Thoracic Dis (Crosstalk between the thoracic physician and the surgeon: perspectives on pulmonary infections, malignancy and chest surgery)"},{"issue":"Suppl 2","key":"2460_CR3","doi-asserted-by":"publisher","first-page":"ii1","DOI":"10.1136\/thoraxjnl-2017-210927","volume":"72","author":"CS Haworth","year":"2017","unstructured":"Haworth CS, Banks J, Capstick T, Fisher AJ, Gorsuch T, Laurenson IF, et al. British thoracic society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax. 2017;72(Suppl 2):ii1\u2013ii64. https:\/\/doi.org\/10.1136\/thoraxjnl-2017-210927.","journal-title":"Thorax"},{"issue":"161","key":"2460_CR4","doi-asserted-by":"publisher","first-page":"210010","DOI":"10.1183\/16000617.0010-2021","volume":"30","author":"JD Chalmers","year":"2021","unstructured":"Chalmers JD, van Ingen J, van der Laan R, Herrmann J-L. Liposomal drug delivery to manage nontuberculous mycobacterial pulmonary disease and other chronic lung infections. Eur Resp Review. 2021;30(161):210010. https:\/\/doi.org\/10.1183\/16000617.0010-2021.","journal-title":"Eur Resp Review"},{"key":"2460_CR5","doi-asserted-by":"publisher","unstructured":"Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ Jr, Andrejak C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline. Eur Respir J. 2020;56(1Doi). https:\/\/doi.org\/10.1183\/13993003.00535-2020.","DOI":"10.1183\/13993003.00535-2020"},{"issue":"4","key":"2460_CR6","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","volume":"175","author":"DE Griffith","year":"2007","unstructured":"Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175(4):367\u2013416. https:\/\/doi.org\/10.1164\/rccm.200604-571ST.","journal-title":"Am J Respir Crit Care Med"},{"issue":"04","key":"2460_CR7","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1055\/s-0041-111494","volume":"70","author":"N Schoenfeld","year":"2016","unstructured":"Schoenfeld N, Haas W, Richter E, Bauer T, Boes L, Castell S, et al. Recommendations of the german Central Committee against Tuberculosis (DZK) and the german respiratory society (DGP) for the diagnosis and treatment of non-tuberculous mycobacterioses. Pneumologie. 2016;70(04):250\u201376. https:\/\/doi.org\/10.1055\/s-0041-111494.","journal-title":"Pneumologie"},{"issue":"1","key":"2460_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1513\/AnnalsATS.201304-085OC","volume":"11","author":"J Adjemian","year":"2014","unstructured":"Adjemian J, Prevots DR, Gallagher J, Heap K, Gupta R, Griffith D. Lack of adherence to evidence-based treatment guidelines for nontuberculous mycobacterial lung disease. Annals of the American Thoracic Society. 2014;11(1):9\u201316. https:\/\/doi.org\/10.1513\/AnnalsATS.201304-085OC.","journal-title":"Annals of the American Thoracic Society"},{"issue":"2","key":"2460_CR9","doi-asserted-by":"publisher","first-page":"1601855","DOI":"10.1183\/13993003.01855-2016","volume":"49","author":"J van Ingen","year":"2017","unstructured":"van Ingen J, Wagner D, Gallagher J, Morimoto K, Lange C, Haworth CS, et al. Poor adherence to management guidelines in nontuberculous mycobacterial pulmonary diseases. Eur Resp J. 2017;49(2):1601855. https:\/\/doi.org\/10.1183\/13993003.01855-2016.","journal-title":"Eur Resp J"},{"issue":"4","key":"2460_CR10","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.chest.2018.01.024","volume":"153","author":"R Diel","year":"2018","unstructured":"Diel R, Nienhaus A, Ringshausen FC, Richter E, Welte T, Rabe KF, et al. Microbiologic Outcome of Interventions against Mycobacterium avium Complex Pulmonary Disease: a systematic review. Chest. 2018;153(4):888\u2013921. https:\/\/doi.org\/10.1016\/j.chest.2018.01.024.","journal-title":"Chest"},{"issue":"1","key":"2460_CR11","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.chest.2017.04.166","volume":"152","author":"R Diel","year":"2017","unstructured":"Diel R, Ringshausen F, Richter E, Welker L, Schmitz J, Nienhaus A. Microbiological and clinical outcomes of treating Non-Mycobacterium Avium Complex Nontuberculous Mycobacterial Pulmonary Disease: a systematic review and Meta-analysis. Chest. 2017;152(1):120\u201342. https:\/\/doi.org\/10.1016\/j.chest.2017.04.166.","journal-title":"Chest"},{"issue":"8","key":"2460_CR12","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1164\/rccm.200603-450OC","volume":"174","author":"DE Griffith","year":"2006","unstructured":"Griffith DE, Brown-Elliott BA, Langsjoen B, Zhang Y, Pan X, Girard W, et al. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2006;174(8):928\u201334. https:\/\/doi.org\/10.1164\/rccm.200603-450OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"2460_CR13","doi-asserted-by":"publisher","first-page":"1602109","DOI":"10.1183\/13993003.02109-2016","volume":"49","author":"R Diel","year":"2017","unstructured":"Diel R, Jacob J, Lampenius N, Loebinger M, Nienhaus A, Rabe KF, et al. Burden of non-tuberculous mycobacterial pulmonary disease in Germany. Eur Respir J. 2017;49(4):1602109. https:\/\/doi.org\/10.1183\/13993003.02109-2016.","journal-title":"Eur Respir J"},{"issue":"1","key":"2460_CR14","doi-asserted-by":"publisher","first-page":"00097","DOI":"10.1183\/23120541.00097-2019","volume":"6","author":"K Izumi","year":"2020","unstructured":"Izumi K, Morimoto K, Uchimura K, Ato M, Hasegawa N, Mitarai S. Population-based survey of antimycobacterial drug use among patients with non-tuberculosis mycobacterial pulmonary disease. ERJ open research. 2020;6(1):00097\u20132019. https:\/\/doi.org\/10.1183\/23120541.00097-2019.","journal-title":"ERJ open research"},{"key":"2460_CR15","doi-asserted-by":"publisher","first-page":"100178","DOI":"10.1016\/j.jctube.2020.100178","volume":"20","author":"R Diel","year":"2020","unstructured":"Diel R, Obradovic M, Tyler S, Engelhard J, Kostev K. Real-world treatment patterns in patients with nontuberculous mycobacterial lung disease in general and pneumologist practices in Germany. J Clin Tuberc Other Mycobact Dis. 2020;20:100178. https:\/\/doi.org\/10.1016\/j.jctube.2020.100178.","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"issue":"4","key":"2460_CR16","doi-asserted-by":"publisher","first-page":"00466","DOI":"10.1183\/23120541.00466-2021","volume":"7","author":"SMH Zweijpfenning","year":"2021","unstructured":"Zweijpfenning SMH, Kops SEP, Boeree MJ, Kuipers S, van Ingen J, Hoefsloot W, et al. Treatment of severe Mycobacterium avium complex pulmonary disease with adjunctive amikacin and clofazimine versus standard regimen alone: a retrospective study. ERJ Open Research. 2021;7(4):00466\u20132021. https:\/\/doi.org\/10.1183\/23120541.00466-2021.","journal-title":"ERJ Open Research"},{"issue":"2","key":"2460_CR17","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1378\/chest.13-2538","volume":"146","author":"RJ Wallace Jr","year":"2014","unstructured":"Wallace RJ Jr, Brown-Elliott BA, McNulty S, Philley JV, Killingley J, Wilson RW, et al. Macrolide\/Azalide therapy for nodular\/bronchiectatic mycobacterium avium complex lung disease. Chest. 2014;146(2):276\u201382. https:\/\/doi.org\/10.1378\/chest.13-2538.","journal-title":"Chest"},{"key":"2460_CR18","doi-asserted-by":"publisher","first-page":"105899","DOI":"10.1016\/j.rmed.2020.105899","volume":"164","author":"S Aliberti","year":"2020","unstructured":"Aliberti S, Sotgiu G, Castellotti P, Ferrarese M, Pancini L, Pasat A, et al. Real-life evaluation of clinical outcomes in patients undergoing treatment for non-tuberculous mycobacteria lung disease: a ten-year cohort study. Respir Med. 2020;164:105899. https:\/\/doi.org\/10.1016\/j.rmed.2020.105899.","journal-title":"Respir Med"},{"issue":"11","key":"2460_CR19","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1513\/AnnalsATS.201605-344BC","volume":"13","author":"DP Boyle","year":"2016","unstructured":"Boyle DP, Zembower TR, Qi C. Relapse versus Reinfection of Mycobacterium avium Complex Pulmonary Disease. Patient characteristics and Macrolide susceptibility. Ann Am Thorac Soc. 2016;13(11):1956\u201361. https:\/\/doi.org\/10.1513\/AnnalsATS.201605-344BC.","journal-title":"Ann Am Thorac Soc"},{"issue":"6","key":"2460_CR20","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1128\/AAC.04577-14","volume":"59","author":"BY Lee","year":"2015","unstructured":"Lee BY, Kim S, Hong Y, Lee SD, Kim WS, Kim DS, et al. Risk factors for recurrence after successful treatment of Mycobacterium avium complex lung disease. Antimicrob Agents Chemother. 2015;59(6):2972\u20137. https:\/\/doi.org\/10.1128\/AAC.04577-14.","journal-title":"Antimicrob Agents Chemother"},{"key":"2460_CR21","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.rmed.2019.10.002","volume":"158","author":"K Morimoto","year":"2019","unstructured":"Morimoto K, Izumi K, Ato M, Hasegawa N, Mitarai S. Actual practice of standard treatment for pulmonary nontuberculous mycobacteriosis in Japan. Respir Med. 2019;158:67\u20139. https:\/\/doi.org\/10.1016\/j.rmed.2019.10.002.","journal-title":"Respir Med"},{"issue":"4","key":"2460_CR22","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.jiac.2019.10.009","volume":"26","author":"H Igari","year":"2020","unstructured":"Igari H, Yamagishi K, Yamazaki S, Murata S, Yahaba M, Takayanagi S, et al. A retrospective observational study of antimicrobial treatment for non-tuberculous mycobacteria disease using a nationwide claims database in Japan. J Infect Chemother. 2020;26(4):349\u201352. https:\/\/doi.org\/10.1016\/j.jiac.2019.10.009.","journal-title":"J Infect Chemother"},{"issue":"4","key":"2460_CR23","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.4951","volume":"29","author":"T Iwao","year":"2020","unstructured":"Iwao T, Kato G, Ito I, Aramaki E, Kuroda T. A survey of clarithromycin monotherapy and long-term administration of ethambutol for patients with MAC lung disease in Japan: a retrospective cohort study using the database of health insurance claims. Pharmacoepidemiol Drug Saf. 2020;29(4):427\u201332. https:\/\/doi.org\/10.1002\/pds.4951.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"suppl 63","key":"2460_CR24","doi-asserted-by":"publisher","first-page":"PA2934","DOI":"10.1183\/13993003.congress-2019.PA2934","volume":"54","author":"N Cardinaels","year":"2019","unstructured":"Cardinaels N, Vande Weygaerde Y, Bomans P, Chin T, Van Braeckel E, Lorent N. Adherence to NTM treatment guidelines in three reference centers in Belgium. Eur Respir J. 2019;54(suppl 63):PA2934. https:\/\/doi.org\/10.1183\/13993003.congress-2019.PA2934.","journal-title":"Eur Respir J"},{"key":"2460_CR25","doi-asserted-by":"publisher","unstructured":"Daley CL. Mycobacterium avium Complex Disease. Microbiol Spectr. 2017;5(2). https:\/\/doi.org\/10.1128\/microbiolspec.TNMI7-0045-2017.","DOI":"10.1128\/microbiolspec.TNMI7-0045-2017"},{"issue":"1","key":"2460_CR26","doi-asserted-by":"publisher","first-page":"e256","DOI":"10.1093\/cid\/ciaa1361","volume":"73","author":"J van Ingen","year":"2021","unstructured":"van Ingen J, Aliberti S, Andrejak C, Chalmers JD, Codecasa LR, Daley CL, et al. Management of drug toxicity in Mycobacterium avium Complex Pulmonary Disease: an Expert Panel Survey. Clin Infect Dis. 2021;73(1):e256\u20139. https:\/\/doi.org\/10.1093\/cid\/ciaa1361.","journal-title":"Clin Infect Dis"},{"key":"2460_CR27","unstructured":"Woods GLB-EB, Conville PS, Desmond EP, Hall GS, Lin G, Pfyffer GE et al. (2011) Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes 2nd ed Wayne (PA): Clinical and Laboratory Standards Institute; 2011 Mar Report No: M24-A2"},{"issue":"2","key":"2460_CR28","doi-asserted-by":"publisher","first-page":"117","DOI":"10.15386\/mpr-1201","volume":"92","author":"LA Anghel","year":"2019","unstructured":"Anghel LA, Farcas AM, Oprean RN. An overview of the common methods used to measure treatment adherence. Med Pharm Rep. 2019;92(2):117\u201322. https:\/\/doi.org\/10.15386\/mpr-1201.","journal-title":"Med Pharm Rep"},{"key":"2460_CR29","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.rmed.2017.08.031","volume":"131","author":"S Zweijpfenning","year":"2017","unstructured":"Zweijpfenning S, Kops S, Magis-Escurra C, Boeree MJ, van Ingen J, Hoefsloot W. Treatment and outcome of non-tuberculous mycobacterial pulmonary disease in a predominantly fibro-cavitary disease cohort. Respir Med. 2017;131:220\u20134. https:\/\/doi.org\/10.1016\/j.rmed.2017.08.031.","journal-title":"Respir Med"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-023-02460-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-023-02460-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-023-02460-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T12:02:48Z","timestamp":1687262568000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-023-02460-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,20]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2460"],"URL":"https:\/\/doi.org\/10.1186\/s12890-023-02460-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2309853\/v1","asserted-by":"object"}]},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,20]]},"assertion":[{"value":"24 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"At the time this research was finalized, Elena Dacheva was an employee of IQVIA Netherlands. Marieke Krol is a current employee of IQVIA Netherlands. Marko Obradovic and Roald van der Laan are current employees of Insmed B.V. The authors report no further conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}},{"value":"All the research activities were performed in accordance with the declaration of Helsinki.This non-interventional study analyzing anonymous data will not include people, medical records, or human tissue, therefore this study does not fall into the scope of the Dutch Medical Research Involving Human Subjects Act (Wet medisch-wetenschappelijk onderzoek met mensen: WMO). Ethical approval is, consequently, not required in the Netherlands. The anonymization and use of the data will be conducted compliant with Dutch data privacy law (Wet bescherming persoonsgegevens: Wbp). IQVIA and Radboud UMC will follow all relevant local privacy requirements. Furthermore, the database used for the study has in-built anonymization processes, managed by a trusted third party. This guarantees that the raw data and final deliverables cannot be traced to an identifiable patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"218"}}